Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

Remco Nagel; Abhijeet Pataskar; Julien Champagne; Reuven Agami

doi:10.1158/0008-5472.CAN-22-1525

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

Remco Nagel, Abhijeet Pataskar, Julien Champagne, Reuven Agami^*

^*Corresponding author for this work

Molecular Genetics

Research output: Contribution to journal › Review article › Academic › peer-review

2 Citations (Scopus)

6 Downloads (Pure)

Abstract

Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.

Original language	English
Pages (from-to)	3637-3649
Number of pages	13
Journal	Cancer Research
Volume	82
Issue number	20
DOIs	https://doi.org/10.1158/0008-5472.CAN-22-1525
Publication status	Published - 17 Oct 2022

Bibliographical note

Funding Information:
Funding for the present work was provided by the Dutch Cancer Society (KWF project 13647), the European Research Council (ERC-2018-ADG-GA 832844), and the AVL Foundation.

Publisher Copyright:
©2022 The Authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/0008-5472.CAN-22-1525Licence: CC BY-NC-ND

Boosting Antitumor Immunity with an Expanded Neoepitope LandscapeFinal published version, 720 KBLicence: CC BY-NC-ND

Cite this

@article{4d19777a5ca84af4be4f3699b2250344,

title = "Boosting Antitumor Immunity with an Expanded Neoepitope Landscape",

abstract = "Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.",

author = "Remco Nagel and Abhijeet Pataskar and Julien Champagne and Reuven Agami",

note = "Funding Information: Funding for the present work was provided by the Dutch Cancer Society (KWF project 13647), the European Research Council (ERC-2018-ADG-GA 832844), and the AVL Foundation. Publisher Copyright: {\textcopyright}2022 The Authors.",

year = "2022",

month = oct,

day = "17",

doi = "10.1158/0008-5472.CAN-22-1525",

language = "English",

volume = "82",

pages = "3637--3649",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

AU - Nagel, Remco

AU - Pataskar, Abhijeet

AU - Champagne, Julien

AU - Agami, Reuven

N1 - Funding Information: Funding for the present work was provided by the Dutch Cancer Society (KWF project 13647), the European Research Council (ERC-2018-ADG-GA 832844), and the AVL Foundation. Publisher Copyright: ©2022 The Authors.

PY - 2022/10/17

Y1 - 2022/10/17

N2 - Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.

AB - Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.

UR - http://www.scopus.com/inward/record.url?scp=85142388452&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-22-1525

DO - 10.1158/0008-5472.CAN-22-1525

M3 - Review article

C2 - 35904353

AN - SCOPUS:85142388452

SN - 0008-5472

VL - 82

SP - 3637

EP - 3649

JO - Cancer Research

JF - Cancer Research

IS - 20

ER -

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this